Harrow Health (NASDAQ:HROW) Stock Rating Upgraded by ValuEngine

Harrow Health (NASDAQ:HROW) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Wednesday, ValuEngine reports.

HROW has been the subject of a number of other reports. Zacks Investment Research upgraded Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Friday, September 6th. Lake Street Capital set a $15.00 price target on Harrow Health and gave the company a “buy” rating in a report on Friday, August 16th.

HROW traded up $0.22 on Wednesday, reaching $6.35. 244,397 shares of the company’s stock were exchanged, compared to its average volume of 278,742. Harrow Health has a twelve month low of $2.22 and a twelve month high of $8.99. The stock has a market cap of $144.70 million, a PE ratio of 10.41 and a beta of 0.15. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.87 and a quick ratio of 3.60. The stock’s fifty day moving average price is $6.22 and its 200-day moving average price is $6.06.



Harrow Health (NASDAQ:HROW) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). Harrow Health had a net margin of 51.32% and a return on equity of 50.32%. The business had revenue of $13.52 million during the quarter, compared to analyst estimates of $12.55 million. As a group, research analysts predict that Harrow Health will post -0.06 earnings per share for the current fiscal year.

In other Harrow Health news, Director Robert J. Kammer sold 6,500 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $7.91, for a total value of $51,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.43% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. FineMark National Bank & Trust purchased a new stake in shares of Harrow Health in the first quarter valued at about $113,000. H D Vest Advisory Services acquired a new stake in Harrow Health during the second quarter worth about $123,000. Stone Ridge Asset Management LLC raised its stake in Harrow Health by 35.2% during the second quarter. Stone Ridge Asset Management LLC now owns 14,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,874 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Harrow Health during the second quarter worth about $138,000. Finally, Wells Fargo & Company MN purchased a new position in Harrow Health during the second quarter worth about $158,000. 34.41% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Featured Story: Trading Ex-Dividend Strategy

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.